Mallinckrodt and Endo to Combine to Create a Global, Scaled ...
Mar 13, 2025 · Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after the close of the transaction and intend to separate that …
Endo - Home | Introducing Keenova and Par Health
Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products. Stay tuned for updates.
Mallinckrodt and Endo Announce Significant Progress in Proposed …
As announced on March 13, 2025, the proposed Mallinckrodt and Endo transaction envisions the spin-off of the combined generic pharmaceuticals businesses and Endo's sterile injectables business into …
Investors | Endo - Overview
Oct 9, 2025 · Mallinckrodt and Endo have merged to create a global, scaled, diversified therapeutics leader. Visit our new Investor Relations website at ir.mallinckrodt.com for up-to-date investor …
Endo Completes International Pharmaceuticals Business Divestiture
Jun 17, 2025 · Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these …
Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 ...
Mar 31, 2025 · Copies of the Company's press releases and additional information about the Company are available at www.endo.com or you can contact the Company's Investor Relations Department at …
Endo Reports Fourth-Quarter and Full-Year 2024 Financial Results
Mar 13, 2025 · Endo is providing the following financial guidance for the full year ending December 31, 2025 based on Endo's current views, beliefs, estimates and assumptions.
Mallinckrodt Receives Necessary Ruling from Irish High Court to …
Jul 17, 2025 · With these approvals in hand, Mallinckrodt and Endo expect to complete their combination in early August, pending the satisfaction of the remaining closing steps. Mallinckrodt's headquarters …
Endo Receives U.S. FDA Approval of Manufacturing Facility in Indore ...
Dec 9, 2024 · Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these …
Investors | Endo - Press Releases
Aug 1, 2025 · On a per share basis, Endo shareholders are entitled to receive approximately $1.31 in cash and 0.2575 of Mallinckrodt shares. Endo shares have ceased trading on the OTCQX.